Key facts
- Frazier Life Sciences Public Fund, L.P. filed SCHEDULE 13G for Aura Biosciences, Inc. Common Stock, $0.00001 par value per share (AURA).
- Disclosed ownership: 9.9%.
- Date of event: 16 May 2025.
Key filing fact
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Frazier Life Sciences Public Fund, L.P. | 6.1% | 3,855,722 | 0 | 3,855,722 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P. | |
| FHMLSP, L.P. | 6.1% | 3,855,722 | 0 | 3,855,722 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P. | |
| FHMLSP, L.L.C. | 6.1% | 3,855,722 | 0 | 3,855,722 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP, L.L.C. | |
| Frazier Life Sciences Public Overage Fund, L.P. | 1.8% | 1,137,454 | 0 | 1,137,454 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P. | |
| FHMLSP Overage, L.P. | 1.8% | 1,137,454 | 0 | 1,137,454 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P. | |
| FHMLSP Overage, L.L.C. | 1.8% | 1,137,454 | 0 | 1,137,454 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C. | |
| Frazier Life Sciences X, L.P. | 0.3% | 159,155 | 0 | 159,155 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P. | |
| FHMLS X, L.P. | 0.3% | 159,155 | 0 | 159,155 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P. | |
| FHMLS X, L.L.C. | 0.3% | 159,155 | 0 | 159,155 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS X, L.L.C. | |
| Frazier Life Sciences XI, L.P. | 0.7% | 423,782 | 0 | 423,782 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P. | |
| FHMLS XI, L.P. | 0.7% | 423,782 | 0 | 423,782 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P. | |
| FHMLS XI, L.L.C. | 0.7% | 423,782 | 0 | 423,782 | /s/ Steve R. Bailey | By Steve R. Bailey, CFO of FHMLS XI, L.L.C. | |
| Frazier Life Sciences XII, L.P. | 1.2% | 739,565 | 0 | 739,565 | /s/ Gordon Empey | By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P., GP of Frazier Life Sciences XII, L.P. | |
| FHMLS XII, L.P. | 1.2% | 739,565 | 0 | 739,565 | /s/ Gordon Empey | By Gordon Empey, General Counsel of FHMLS XII, L.L.C., GP of FHMLS XII, L.P. | |
| FHMLS XII, L.L.C. | 1.2% | 739,565 | 0 | 739,565 | /s/ Gordon Empey | By Gordon Empey, General Counsel of FHMLS XII, L.L.C. | |
| James N. Topper | 9.9% | 6,315,678 | 0 | 6,315,678 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017 | |
| Patrick J. Heron | 9.9% | 6,315,678 | 0 | 6,315,678 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017 | |
| Albert Cha | 7.9% | 4,993,176 | 0 | 4,993,176 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021 | |
| James Brush | 7.9% | 4,993,176 | 0 | 4,993,176 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021 | |
| Daniel Estes | 1.9% | 1,163,347 | 0 | 1,163,347 | /s/ Steve R. Bailey | By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022 |
CIK / CUSIP context first